Dupont De Nemours Stock Earnings Reports

DuPont delivered a stronger-than-expected start to 2026: Q1 net sales of $1.7B (up 4% YoY, 2% organic), operating EBITDA of $414M (up 15% YoY) and double-digit adjusted EPS growth. Organic growth was driven by Health Care & Water (notably medical packaging and biopharma) and aerospace; Diversified Industrials was roughly flat organically with weakness in construction offset by aerospace and automotive (EV battery adhesives). Margin expansion benefited from favorable mix (~50 bps) and productivity (~70 bps). Management raised full-year guidance (midpoint net sales ~$7.185B; operating EBITDA midpoint ~$1.745B; adjusted EPS $2.35–$2.40) and announced a $275M accelerated share repurchase under the existing program. Company expects to offset roughly $90M of incremental input/transportation costs (driven by the Middle East conflict) via pricing and surcharges, with most actions phased in starting May; free cash flow conversion target remains >90% for the year. The Aramids divestiture closed April 1 (~$1.1B net proceeds), contributing to interest income and balance sheet flexibility for buybacks or M&A. Near-term risks include Middle East logistics disruption (some Q1 shipments delayed, largely mitigated) and currency headwinds, but management emphasizes operational improvements, digital/AI investments, and continued focus on productivity and portfolio optimization (80/20 work in Diversified Industrials).